Inito, an at-home diagnostics company best known for its fertility monitoring system, has raised $29 million in Series B funding as it prepares to move beyond fertility into a wider set of hormone and health tests using AI-engineered antibodies, the company said in a statement.
The round was led by Bertelsmann India Investments and co-led by existing investor Fireside Ventures, taking Inito’s total equity funding to $45 million, according to the release.
From fertility monitoring to a broader diagnostics platform
Inito said it launched its first fertility monitor in 2021 with an aim to bring quantitative hormone diagnostics into homes. Since then, the company says its platform has analyzed more than 30 million hormone data points and can measure FSH, estrogen, LH, and PdG (a urine metabolite of progesterone), with AI models interpreting these measurements to surface hormone patterns for users.
Now, Inito is positioning that hormone dataset and consumer platform as a foundation for a broader at-home diagnostics push. The company said it is “moving beyond fertility” to build an at-home hormone and health diagnostics platform powered by AI-engineered antibodies.
Why the company is betting on “AI-engineered antibodies”
Inito’s announcement frames its next phase around rethinking how diagnostic tests are built. Conventional antibody development, the company said, relies on animal-based processes and manual lab screening that can be slow, costly, and hard to control, with issues like batch variability, breakdown over time, and limited sensitivity for many at-home biomarkers.
By contrast, the company described an approach based on computational protein design and machine learning models that predict protein folding and binding, enabling the creation of synthetic antibodies it claims can be more sensitive and consistent than legacy methods, an advance it argues could remove long-standing bottlenecks in diagnostics innovation.
“We have always believed that healthcare should start at home,” co-founders Aayush Rai and Varun AV said, adding that while hormones influence areas like “fertility, mood, metabolism, sleep, and energy,” reliable testing still largely depends on clinic infrastructure. The founders said AI-engineered antibodies can help build diagnostic tests “that simply were not possible before.”
What the new capital will be used for
Inito said the funding will accelerate its work on designing diagnostic tests in silico, rather than through slower, animal-based development methods, and expand the range of at-home tests it can bring to more users globally.
Investors backing the round echoed the company’s positioning at the intersection of deep science, AI, and consumer health. Swati Murarka, Principal at Bertelsmann India Investments, said Inito is “redefining diagnostics for the modern world” by combining “clinical precision with intelligent design.”
Kannan Sitaram, Co-founder & Partner at Fireside Ventures, said the firm has seen Inito grow into a women’s health brand built on “deep consumer insight and scientific accuracy,” and reaffirmed support as the company scales globally.
Company snapshot
Inito describes itself as an at-home diagnostics technology company whose flagship product helps users interpret hormone levels and confirm ovulation. It also said it is expanding into areas such as testosterone, vitamins, and thyroid, among others, and has 20+ patents, a database of over 30 million fertility hormone tests, and teams across Dubai, Bangalore, and London.
Also Read: Adani Group Unveils Solar Park in Khavda 5 Times the Size of Paris
